Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas

Area of Science:

• Oncology
• Genetics
• Dermatology

Background:

• Metastatic melanoma treatment is advancing with new targeted therapies.
• Effective patient stratification is essential to maximize therapeutic benefits.
• Current screening often focuses solely on BRAF V600E mutations.

Purpose of the Study:

• To highlight the importance of comprehensive molecular profiling beyond BRAF V600E in metastatic melanoma.
• To present a practical approach for stratifying patients for targeted therapy.
• To discuss the role of non-V600E BRAF mutations and other genetic alterations.

Main Methods:

• Review of clinical experience in molecularly profiling metastatic melanoma patients.
• Development of a practical flowchart for genetic mutation screening.
• Analysis of patient response based on mutation status.

Main Results:

• Non-V600E BRAF mutations (e.g., K-R-M-D) can predict response to targeted therapy, similar to V600E.
• Other mutations including N-RAS, KIT, and GNAQ are relevant in specific melanoma subtypes.
• A proposed flowchart aids in systematic molecular stratification.

Conclusions:

• Comprehensive molecular screening, including non-V600E BRAF and other key genes, improves patient selection for targeted melanoma therapy.
• The developed flowchart provides a practical guide for clinicians.
• Accurate stratification enhances treatment efficacy in metastatic melanoma.